Another great point/post...this time by Tony over on Yahoo...
"Novalere is taking a big if not bigger risk, if Fluticare was to be rejected they would be locked in until Q2 unable to sell, while INNV sinks like a stone, unless there is a clause in that 10Q that states otherwise (I'll have to look into that)... Either way, it seems like both companies are very confident in a near term approval."
** Never looked at it from this perspective...If Novalere is truly locked up until 4/1/17 by taking those ANDA shares early - think of the chance THEY are taking, if it was denied.
Logically thinking this through Tony is right - BOTH companies have to be pretty darn confident here that it WILL BE APPROVED fairly soon. The risk/reward ratio is leaning more towards UPSIDE IMO with BH platform and new products doing so well. GLTA